Wikipedia

PB-22

(Redirected from QUPIC)

PB-22 (QUPIC, SGT-21 or 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester) is a designer drug offered by online vendors as a cannabimimetic agent, and detected being sold in synthetic cannabis products in Japan in 2013.[1][2] PB-22 represents a structurally unique synthetic cannabinoid chemotype, since it contains an ester linker at the indole 3-position, rather than the precedented ketone of JWH-018 and its analogs, or the amide of APICA and its analogs.

PB-22
Legal status
Legal status
Identifiers
  • 1-Pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester
CAS Number
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.233.114 Edit this at Wikidata
Chemical and physical data
FormulaC23H22N2O2
Molar mass358.441 g·mol−1
3D model (JSmol)
  • CCCCCN1C=C(C2=CC=CC=C21)C(=O)OC3=CC=CC4=C3N=CC=C4
  • InChI=1S/C23H22N2O2/c1-2-3-6-15-25-16-19(18-11-4-5-12-20(18)25)23(26)27-21-13-7-9-17-10-8-14-24-22(17)21/h4-5,7-14,16H,2-3,6,15H2,1H3
  • Key:ZAVGICCEAOUWFM-UHFFFAOYSA-N

PB-22 has an EC50 of 5.1 nM for human CB1 receptors, and 37 nM for human CB2 receptors.[3] PB-22 produces bradycardia and hypothermia in rats at doses of 0.3–3 mg/kg, suggesting potent cannabinoid-like activity.[3] The magnitude and duration of hypothermia induced in rats by PB-22 was notably greater than JWH-018, AM-2201, UR-144, XLR-11, APICA, or STS-135, with a reduction of body temperature still observable six hours after dosing.[3] One clinical toxicology study found PB-22 to be the cause of seizures in a human and his dog.[4]

History

edit

PB-22 was originally developed by New Zealand legal highs company Stargate International in 2012 as SGT-21, intended to be a structural hybrid of QMPSB and JWH-018.[5] However, no intellectual property protection was applied for and the compound quickly became subject to widespread grey-market sales outside the control of the inventors.

Detection

edit

A forensic standard of PB-22 is available, and the compound has been posted on the Forendex website of potential drugs of abuse.[6]

edit

As of 9 May 2014, PB-22 is no longer legal in New Zealand.[7]

In January 2014, PB-22 was designated as a Schedule I controlled substance in the United States.[8][9]

In Ohio, PB-22 is illegal.[10]

Florida also has banned PB-22.[11]

Since 13 December 2014 it is also illegal in Germany because of adding the substance to the BtMG Anlage II.

As of October 2015 PB-22 is a controlled substance in China.[12]

See also

edit

References

edit
  1. ^ Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2013). "Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products". Forensic Toxicology. 31 (2): 223–240. doi:10.1007/s11419-013-0182-9. S2CID 1279637.223-240&rft.date=2013&rft_id=info:doi/10.1007/s11419-013-0182-9&rft_id=https://api.semanticscholar.org/CorpusID:1279637#id-name=S2CID&rft.aulast=Uchiyama&rft.aufirst=N&rft.au=Matsuda, S&rft.au=Kawamura, M&rft.au=Kikura-Hanajiri, R&rft.au=Goda, Y&rfr_id=info:sid/en.wikipedia.org:PB-22" class="Z3988">
  2. ^ Lin M, Ellis B, Eubanks LM, Janda KD (July 2021). "Pharmacokinetic Approach to Combat the Synthetic Cannabinoid PB-22". ACS Chemical Neuroscience. 12 (14): 2573–2579. doi:10.1021/acschemneuro.1c00360. PMID 34254505. S2CID 235808519.2573-2579&rft.date=2021-07&rft_id=https://api.semanticscholar.org/CorpusID:235808519#id-name=S2CID&rft_id=info:pmid/34254505&rft_id=info:doi/10.1021/acschemneuro.1c00360&rft.aulast=Lin&rft.aufirst=M&rft.au=Ellis, B&rft.au=Eubanks, LM&rft.au=Janda, KD&rfr_id=info:sid/en.wikipedia.org:PB-22" class="Z3988">
  3. ^ a b c Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, et al. (August 2015). "Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135". ACS Chemical Neuroscience. 6 (8): 1445–1458. doi:10.1021/acschemneuro.5b00107. PMID 25921407.1445-1458&rft.date=2015-08&rft_id=info:doi/10.1021/acschemneuro.5b00107&rft_id=info:pmid/25921407&rft.aulast=Banister&rft.aufirst=SD&rft.au=Stuart, J&rft.au=Kevin, RC&rft.au=Edington, A&rft.au=Longworth, M&rft.au=Wilkinson, SM&rft.au=Beinat, C&rft.au=Buchanan, AS&rft.au=Hibbs, DE&rft.au=Glass, M&rft.au=Connor, M&rft.au=McGregor, IS&rft.au=Kassiou, M&rft_id=https://zenodo.org/record/47750&rfr_id=info:sid/en.wikipedia.org:PB-22" class="Z3988">
  4. ^ Gugelmann H, Gerona R, Li C, Tsutaoka B, Olson KR, Lung D (July 2014). "'Crazy Monkey' poisons man and dog: Human and canine seizures due to PB-22, a novel synthetic cannabinoid". Clinical Toxicology. 52 (6): 635–638. doi:10.3109/15563650.2014.925562. PMID 24905571. S2CID 207647659.635-638&rft.date=2014-07&rft_id=https://api.semanticscholar.org/CorpusID:207647659#id-name=S2CID&rft_id=info:pmid/24905571&rft_id=info:doi/10.3109/15563650.2014.925562&rft.aulast=Gugelmann&rft.aufirst=H&rft.au=Gerona, R&rft.au=Li, C&rft.au=Tsutaoka, B&rft.au=Olson, KR&rft.au=Lung, D&rfr_id=info:sid/en.wikipedia.org:PB-22" class="Z3988">
  5. ^ Brandt SD, Kavanagh PV, Westphal F, Dreiseitel W, Dowling G, Bowden MJ, Williamson JP (January 2021). "Synthetic cannabinoid receptor agonists: Analytical profiles and development of QMPSB, QMMSB, QMPCB, 2F-QMPSB, QMiPSB, and SGT-233". Drug Testing and Analysis. 13 (1): 175–196. doi:10.1002/dta.2913. PMID 32880103.175-196&rft.date=2021-01&rft_id=info:doi/10.1002/dta.2913&rft_id=info:pmid/32880103&rft.aulast=Brandt&rft.aufirst=SD&rft.au=Kavanagh, PV&rft.au=Westphal, F&rft.au=Dreiseitel, W&rft.au=Dowling, G&rft.au=Bowden, MJ&rft.au=Williamson, JP&rft_id=https://doi.org/10.1002%2Fdta.2913&rfr_id=info:sid/en.wikipedia.org:PB-22" class="Z3988">
  6. ^ Forendex entry, Southern Association of Forensic Scientists
  7. ^ Jones N (1 May 2014). "Legal highs pulled from shelves". New Zealand Herald. New Zealand Media and Entertainment. Retrieved 18 August 2020.
  8. ^ Behonick G, Shanks KG, Firchau DJ, Mathur G, Lynch CF, Nashelsky M, et al. (October 2014). "Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22". Journal of Analytical Toxicology. 38 (8): 559–562. doi:10.1093/jat/bku048. PMC 4334789. PMID 24876364.559-562&rft.date=2014-10&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334789#id-name=PMC&rft_id=info:pmid/24876364&rft_id=info:doi/10.1093/jat/bku048&rft.aulast=Behonick&rft.aufirst=G&rft.au=Shanks, KG&rft.au=Firchau, DJ&rft.au=Mathur, G&rft.au=Lynch, CF&rft.au=Nashelsky, M&rft.au=Jaskierny, DJ&rft.au=Meroueh, C&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334789&rfr_id=info:sid/en.wikipedia.org:PB-22" class="Z3988">
  9. ^ "PB-22 and 5F-PB-22" (PDF). Drug Enforcement Administration, Office of Diversion Control.
  10. ^ Pelzer J (April 17, 2014). "Ohio bans two synthetic marijuana drugs sold as "herbal incense"". cleveland.com.
  11. ^ "Statutes & Constitution :View Statutes : Online Sunshine". Leg.state.fl.us. 1997-05-06. Retrieved 2014-07-12.
  12. ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
Retrieved from "https://en.wikipedia.org/w/index.php?title=PB-22&oldid=1155444955"